Gene therapy for lysosomal storage diseases
- 9 August 2025
- journal article
- review article
- Published by Elsevier in Brain and Development
- Vol. 47 (5) , 104399
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Unifying biology of neurodegeneration in lysosomal storage diseasesJournal of Inherited Metabolic Disease, 2025
- Multi-year enzyme expression in patients with mucopolysaccharidosis type VI after liver-directed gene therapyMed, 2024
- Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United StatesCytotherapy, 2024
- Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1/2 studyMolecular Genetics and Metabolism, 2023
- 261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The NetherlandsNeuromuscular Disorders, 2023
- First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia BMolecular Therapy, 2022
- Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded accessThe Lancet, 2022
- Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II miceMolecular Therapy, 2021
- Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trialThe Lancet Neurology, 2017
- Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: A nationwide survey in JapanMolecular Genetics and Metabolism, 2012